Brilinta Clinical Experience Investigation - BRLCEIACS/OMI

Study identifier:D5133N00007

ClinicalTrials.gov identifier:NCT03212287

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Brilinta tablets 60mg/90mg Clinical Experience Investigation

Medical condition

acute coronary syndrome, old myocardial infarction

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

566

Study type

Observational

Age

16 Years - 130 Years

Date

Study Start Date: 21 Dec 2017
Estimated Primary Completion Date: 30 Mar 2028
Estimated Study Completion Date: 30 Mar 2028

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria